All partnering requests
Private Company
Therapeutics, biomarkers and models for chronic kidney disease
  • Background
  • What we're looking for
  • What we can offer you
  • Q&A
Have questions about this request?
Get them answered by the team at the company.
Background

Chronic kidney disease (CKD) is a progressive loss of kidney function that is common in older cats. Although renal diets and treatments for proteinuria, hypertension, dehydration and other complications can improve outcomes, they generally manage consequences of kidney dysfunction rather than restore lost renal function. Long-term care may also require multiple medications or frequent dosing, creating challenges for cats and caregivers. There is a need for practical treatments that slow, halt or potentially reverse progression, ideally from early stages. 

 

Early detection represents another important challenge. Creatinine can rise late and is affected by muscle mass; symmetric dimethylarginine (SDMA) can detect reduced filtration earlier but is not specific to CKD. Urine protein, urine concentration and imaging provide additional clues, yet may be variable, nonspecific or inconclusive in early disease. Novel, validated biomarkers could more reliably identify early CKD, distinguish it from other renal abnormalities and help guide intervention. 

 

Additionally, access to reliable feline-specific in vitro and in vivo CKD models remains a challenge for research and therapeutic development. More representative models could facilitate understanding of disease mechanisms and support evaluation of emerging treatments. 

 

Addressing these interconnected gaps could advance the detection, study and treatment of feline CKD.

What we're looking for

We are looking for innovative solutions to advance the treatment, early detection, and study of feline chronic kidney disease (CKD). Our ultimate goal is to identify and bring to market disease-modifying therapeutics capable of slowing, halting, or potentially reversing CKD progression.

We are also interested in novel biomarkers enabling earlier and more specific disease detection, particularly at International Renal Interest Society (IRIS) stages 1–2, as well as in vitro and in vivo models that support CKD research and therapeutic development. For biomarkers and disease models, we welcome collaborations with experts whose approaches have been explored in other species and could potentially be adapted to cats, even if feline-specific validation has not yet been conducted.

Solutions of interest include:
  • Novel therapeutic assets to slow or reverse feline CKD
  • Novel biomarkers for early and specific CKD detection
  • Feline CKD in vitro and in vivo models or adaptable platforms
Our must-have requirements are:
  • Therapeutic assets must provide preliminary data or compelling evidence of their potential to slow, halt, or reverse the progression of feline CKD
  • Therapeutic assets/APIs must support the potential for oral dosing weekly or less frequently, or injectable dosing monthly or less frequently, avoiding daily administration
  • Novel blood- or urine-based biomarkers must enable early CKD detection and/or progression monitoring, with feline applicability or a credible rationale and willingness to investigate their use in cats
  • In vitro or in vivo CKD models must demonstrate feline applicability, or a credible rationale and willingness to collaborate on adapting and evaluating models from other species in cats
Our nice-to-have's are:
  • Preclinical or clinical data demonstrating therapeutic efficacy, safety, or pharmacokinetics in cats, ideally including relevant CKD endpoints
  • Teams with demonstrated expertise in CKD, renal biology, feline medicine, or veterinary drug development, including access to relevant research or clinical networks
  • Preliminary evidence of biomarker sensitivity, specificity, or predictive value for CKD, ideally demonstrating advantages over established markers such as creatinine or SDMA
  • Models that reproduce key features of feline CKD, such as progressive kidney dysfunction or fibrosis, with evidence of suitability for therapeutic evaluation
What's out of scope:
  • Prescription diets, nutritional supplements, probiotics, electrolyte solutions, or other nutritional and supportive interventions without direct disease-modifying potential
  • Treatments exclusively targeting CKD-associated symptoms or complications, such as anemia or sarcopenia, without addressing the underlying kidney disease
  • Wearables, activity trackers, smart litter boxes, or other behavioral and environmental monitoring technologies that do not directly measure CKD-related biological markers
Acceptable technology readiness levels (TRL):
Levels 3-9
What we can offer you
Eligible partnership models:
Sponsored researchCo-developmentSupply/purchaseLicensingFee-for-servicePilot or trial engagementEquity investment
Benefits:
Sponsored Research
Funding could range from $50,000 to $200,000 USD over 1–2 years, including indirect costs, to support therapeutic proof-of-concept, biomarker evaluation, or model adaptation to cats. Larger projects may be considered separately.
Expertise
Partners may have access to experts in veterinary nephrology, renal biology, PK/PD, formulation, biomarker and assay development, disease modeling, and clinical study design, depending on project needs.
Data
Where relevant and available, technical insights may be shared to guide therapeutic development, assess biomarker performance, or support adaptation and validation of CKD research models in cats.
Facilities and Services
Facilities and services may be available for pharmacology and safety studies, sample and biomarker analysis, assay development, and evaluation or adaptation of in vitro/in vivo CKD models, depending on scope and feasibility.
Q&A with the company
Ask the team at the company any questions you have about this partnering request.
Ask your question
Sign up to access the full partnering request.
View the details of this request and connect directly with corporate R&D teams at Fortune 500 companies.
Submit Proposal
Deadline: January 8
Refine recommendations
Is this request relevant to you?
Eligible partners
Academic researchersStartupsSuppliersService providers (CROs/CMOs)Consultants
Seeking partners focused on
AnatomyAgingAnalytical ChemistryBiochemistryBioinformaticsBiological ComplexityBiological Fluid DynamicsBiomolecular ProcessesClinical PharmacologyComputational Biology
34 more

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.